Saxenda on TikTok: separating liraglutide facts from viral hype
Quick answer
The creator is self-documenting day one of Saxenda (liraglutide 3.0mg, injectable GLP-1 agonist) use, describing standard injection technique including flow check and dose setting. They report no immediate adverse effects but note fatigue, a documented early side effect in the SCALE trial, which they attribute instead to pre-existing depression. Their food intake appears calorie-restricted but does not reflect the structured dietary support recommended alongside Saxenda in clinical practice.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @supersxcgemabackupltd actually say?
The creator documented their first day injecting Saxenda (liraglutide), a GLP-1 receptor agonist used for weight management. They said eating a light meal before injecting helps with nausea, described the flow check process, and held the injection for what they believed was around 10 seconds. They also noted feeling tired later in the day but attributed that to depression rather than the medication, which shows some genuine caution about jumping to conclusions.
Throughout the video, they were candid about not being certain: "I don't know, so it's a journey, so we will see." Their food diary for the day included bran flakes, a low-calorie bar, a sandwich with lower-fat crisps, tea, and water. No specific calorie targets or dosing advice were given, which is worth noting.
Does the science back this up?
The claim that eating before injecting reduces nausea is broadly consistent with clinical evidence, though the mechanism is more nuanced than the creator implies. Liraglutide slows gastric emptying, and injecting on a completely empty stomach can intensify nausea in some patients, though the evidence is not watertight on meal timing specifically.
The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) established liraglutide 3.0mg as effective for weight loss, but the majority of the 3,731 participants experienced gastrointestinal side effects, particularly early in treatment. The manufacturer's prescribing information confirms nausea as the most common adverse event, affecting roughly 39% of users. Fatigue is also a documented side effect, appearing in clinical trial data, so the creator's tiredness on day one cannot be dismissed as entirely unrelated to the drug, even if their depression is a plausible confounding factor.
What did they get wrong (or right)?
Credit where it is due: the flow check step they described is correct. Saxenda pens require a flow check before first use to confirm the pen is working and to remove air from the needle. The creator handled this accurately.
Where things get shakier is the "hold for 10 seconds" claim. Novo Nordisk's official Saxenda instructions specify holding the pen in place for at least 6 seconds after the button is fully pressed. Ten seconds is not dangerous, but it is not the stated guidance either. Small inaccuracies in injection technique can affect dose delivery, so getting this right matters.
The food diary the creator shared, a low-calorie bar and a sandwich with reduced-fat crisps, is not evidence of a medically supervised meal plan. Saxenda is typically prescribed alongside structured dietary and behavioural support. Going it alone based on TikTok trial-and-error is not the same as that, and the creator's audience should understand the difference.
What should you actually know?
Saxenda is a prescription-only medication in the UK and most other countries. It requires a licensed prescriber to assess whether it is appropriate for you, including a review of contraindications such as a personal or family history of medullary thyroid carcinoma or MEN2. The SCALE trial population had BMI over 27 with at least one weight-related comorbidity, or BMI over 30. It is not a casual starter kit.
Nausea, vomiting, diarrhoea, and fatigue are the most commonly reported early side effects, and dose escalation schedules exist specifically to reduce their severity. The creator's day-one experience of minimal discomfort is not universal. Davies et al. (2015, Diabetes Care) found that GI events were the primary reason for discontinuation in liraglutide trials.
If you are considering a GLP-1 medication, the conversation starts with a clinician, not a TikTok comment section.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Saxenda on TikTok: separating liraglutide facts from viral hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Saxenda on TikTok: separating liraglutide facts from viral hype is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator is self-documenting day one of Saxenda (liraglutide 3.
FormBlends verdict
The creator is self-documenting day one of Saxenda (liraglutide 3.0mg, injectable GLP-1 agonist) use, describing standard injection technique including flow check and dose setting. They report no immediate adverse effects but note fatigue, a documented early side effect in the SCALE trial, which they attribute instead to pre-existing depression. Their food intake appears calorie-restricted but does not reflect the structured dietary support recommended alongside Saxenda in clinical practice.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is self-documenting day one of Saxenda (liraglutide 3.0mg, injectable GLP-1 agonist) use, describing standard injection technique including flow check and dose setting. They report no immediate adverse effects but note fatigue, a documented early side effect in the SCALE trial, which they attribute instead to pre-existing depression. Their food intake appears calorie-restricted but does not reflect the structured dietary support recommended alongside Saxenda in clinical practice.
- Nausea affects approximately 39% of Saxenda users according to the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM), making it the most common early adverse event, not a minor edge case.
- The Saxenda pen's official instructions specify holding the needle in place for at least 6 seconds after pressing the dose button, not 10 seconds as the creator stated, though 10 seconds is not clinically harmful.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Nausea affects approximately 39% of Saxenda users according to the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM), making it the most common early adverse event, not a minor edge case.
- The Saxenda pen's official instructions specify holding the needle in place for at least 6 seconds after pressing the dose button, not 10 seconds as the creator stated, though 10 seconds is not clinically harmful.
- Fatigue on day one of liraglutide use may be medication-related, not solely due to pre-existing conditions; Davies et al. (2015, Diabetes Care) listed fatigue among early systemic complaints in GLP-1 trials.
- Saxenda is a prescription-only medicine in the UK, indicated for adults with BMI of 30 or above, or BMI of 27 or above with a weight-related health condition, and it requires clinical assessment before prescribing.
- GI side effects are the leading cause of discontinuation in liraglutide trials; structured dose escalation schedules exist specifically to reduce early nausea and improve tolerability.
- Saxenda is licensed as an adjunct to a reduced-calorie diet and increased physical activity, not as a standalone intervention. The dietary approach shown in this video does not represent the supervised support used in clinical trials.
- Saxenda contains liraglutide and is distinct from semaglutide-based medications such as Ozempic or Wegovy. These are different molecules with different dosing, delivery, and trial profiles and should not be treated as interchangeable.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
supersxcgemabackupltd · TikTok creator
167.5K views on this video
#foryou #fyp #saxenda
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by supersxcgemabackupltd, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.